Detalles de la búsqueda
1.
A population pharmacokinetic model for posaconazole intravenous solution and oral powder for suspension formulations in pediatric patients with neutropenia.
Antimicrob Agents Chemother
; 68(4): e0119723, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38376229
2.
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Lancet
; 397(10273): 499-509, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549194
3.
A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole.
Antimicrob Agents Chemother
; 62(7)2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29712663
4.
Voriconazole pharmacogenetics - Authors' reply.
Lancet
; 398(10300): 578-579, 2021 08 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34391493
5.
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
J Antimicrob Chemother
; 72(12): 3406-3413, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28961714
6.
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
J Antimicrob Chemother
; 71(3): 718-26, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26612870
7.
Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.
Antimicrob Agents Chemother
; 59(6): 3385-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25824210
8.
Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.
Antimicrob Agents Chemother
; 59(2): 1246-51, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25512407
9.
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Antimicrob Agents Chemother
; 58(7): 3610-7, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24733463
10.
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.
Antimicrob Agents Chemother
; 58(7): 4020-5, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24798274
11.
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
Antimicrob Agents Chemother
; 58(10): 5758-65, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25049247
12.
Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).
J Pediatric Infect Dis Soc
; 12(6): 334-341, 2023 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37389891
13.
Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis.
Clin Drug Investig
; 43(9): 681-690, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676612
14.
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
J Antimicrob Chemother
; 72(12): 3501, 2017 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29029280
15.
Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer's safety database.
Expert Opin Drug Saf
; 21(8): 1113-1120, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35232318
16.
Erratum for Kersemaekers et al., Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects.
Antimicrob Agents Chemother
; 60(7): 4426, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27325815
17.
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
J Antimicrob Chemother
; 71(6): 1747, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26960721
18.
Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Int J Antimicrob Agents
; 56(3): 106084, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32682946
19.
Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Adv Ther
; 37(5): 2493-2506, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32319040
20.
A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
PLoS One
; 14(3): e0212837, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30913226